Acetylation-dependent regulation of BRAF oncogenic function

Aberrant BRAF activation, including the BRAF(V600E) mutation, is frequently observed in human cancers. However, it remains largely elusive whether other types of post-translational modification(s) in addition to phosphorylation and ubiquitination-dependent regulation also modulate BRAF kinase activity. Here, we report that the acetyltransferase p300 activates the BRAF kinase by promoting BRAF K601 acetylation, a process that is antagonized by the deacetylase SIRT1. Notably, K601 acetylation facilitates BRAF dimerization with RAF proteins and KSR1. Furthermore, K601 acetylation promotes melanoma cell proliferation and contributes to BRAF(V600E) inhibitor resistance in BRAF(V600E) harboring melanoma cells. As such, melanoma patient-derived K601E oncogenic mutation mimics K601 acetylation to augment BRAF kinase activity. Our findings, therefore, uncover a layer of BRAF regulation and suggest p300 hyperactivation or SIRT1 deficiency as potential biomarkers to determine ERK activation in melanomas.

Automated summary

This study reveals that the acetyltransferase p300 activates BRAF kinase by promoting BRAF K601 acetylation, which plays a significant role in melanoma and is associated with resistance to BRAF(V600E) inhibitors.